Kim Huard

This inventor holds 23 USPTO granted patents and 9 published patent applications, plus 6 CIPO patents and 8 EPO patents, primarily in GLP-1 Receptor Agonists. Top assignee: Pfizer Corporation. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kim Huard. Retrieved from https://idiyas.com/inventor/kim-huard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 9)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 12.2

ph-index = 6

Forward Citations = 108(Granted Patents)

Location History:

Medford, MA (US) (2016 - 2019)
Berkeley, CA (US) (2020 - 2024)

Company Filing History:

23 out of 4,488

Pfizer Corporation

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

GLP-1 Receptor Agonists

Diacylglycerol Acyl Transferase

Ketohexokinase Inhibitors

NASH Treatment

NAFLD

Benzodioxol

3-Azabicyclohexanes

Pharmaceutical Compositions

Agonists

Inhibitors

Therapeutics

Drug Development

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703696 - Diacylglycerol acyl transferase 2 inhibitors (2026-08-11),

2. 12611401 - Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases (2026-04-28),

3. 12378230 - GLP-1 receptor agonists and uses thereof (2025-08-05),

4. 12331041 - GLP-1 receptor agonists and uses thereof (2025-06-17),

5. 12319669 - GLP-1 receptor agonists and uses thereof (2025-06-03),

6. 11866425 - Diacylglycerol acyl transferase 2 inhibitors (2024-01-09),

7. 11858916 - GLP-1 receptor agonists and uses thereof (2024-01-02),

8. 11802121 - GLP-1 receptor agonists and uses thereof (2023-10-31),

9. 11634410 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2023-04-25),

10. 11512070 - GLP-1 receptor agonists and uses thereof (2022-11-29),

11. 11034678 - Diacylglycerol acyl transferase 2 inhibitors (2021-06-15),

12. 10988463 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2021-04-27),

13. 10934279 - GLP-1 receptor agonists and uses thereof (2021-03-02),

14. 10851081 - GLP-1 receptor agonists and uses thereof (2020-12-01),

15. 10787438 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2020-09-29),

Title: Kim Huard: Innovating GLP-1 Receptor Agonists

Introduction

Kim Huard, based in Berkeley, CA, is a notable inventor with a remarkable portfolio of 20 patents. His contributions to the field of pharmacology and biochemistry are reshaping the landscape of medical treatments, particularly through his work with GLP-1 receptor agonists.

Latest Patents

Among his latest groundbreaking patents are the formulations of 6-carboxylic acids of benzimidazoles and various derivatives, including 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1 receptor agonists. These patents describe the processes to synthesize these compounds and detail methods for administering them to mammals in need, showcasing significant potential for diabetes and obesity treatments.

Career Highlights

Kim Huard is currently associated with Pfizer Corporation, a leading pharmaceutical company where innovative research plays a crucial role. His extensive work in the field has led to numerous patents that serve as vital tools in drug development, aiding in the discovery of effective therapies.

Collaborations

Throughout his career, Huard has collaborated with talented colleagues like Kentaro Futatsugi and Matthew Scott Dowling. These partnerships highlight the collaborative nature of pharmaceutical research, illustrating how teamwork can lead to transformative advancements in healthcare.

Conclusion

Kim Huard exemplifies the spirit of innovation within the pharmaceutical industry. His impactful patents and collaborations signify a commitment to addressing critical health challenges through research and development. As advancements continue, Huard’s contributions will likely remain influential in the ongoing quest for effective medical solutions.

Profile summary based on public USPTO records.